APO Research
Talk to an analyst

APO RESEARCH · REPORT

Hormone Disorder Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Hormone Disorder Drug Market Outlook and Growth Opportunities 2026

22 December 2025190 pages

Choose your research edition.

Industry ResearchHormone Disorder Drug Industry Research Report 2026134 pages · $2,950 USDIndustry Growth & TrendsGlobal Hormone Disorder Drug Industry Growth and Trends Forecast to 2032111 pages · $3,450 USDMarket StructureGlobal Hormone Disorder Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Hormone Disorder Drug Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Hormone Disorder Drug Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Hormone Disorder Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Hormone Disorder Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Hormone Disorder Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Hormone Disorder Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Hormone Disorder Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Hormone Disorder Drug market include Abbott, Teva Pharmaceutical Industries Ltd, Sun Pharmaceutical Industries Ltd, Sanofi, Novartis AG, Merck KGaA, Lilly, Ferring B.V and PT. Daewoong Pharmaceutical Company, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Hormone Disorder Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Hormone Disorder Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Hormone Disorder Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Hormone Disorder Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Hormone Disorder Drug Segment by Company

Abbott

Teva Pharmaceutical Industries Ltd

Sun Pharmaceutical Industries Ltd

Sanofi

Novartis AG

Merck KGaA

Lilly

Ferring B.V

PT. Daewoong Pharmaceutical Company

Mayne Pharma Group Limited

Ipsen Pharma

Genentech, Inc

F. Hoffmann-La Roche Ltd

Bausch Health Companies Inc

Amneal Pharmaceutical Inc

Hormone Disorder Drug Segment by Type

Growth Hormone Stimulator

Growth Hormone Inhibitor

Hormone Disorder Drug Segment by Application

Dwarfism

Gigantism

Other

Hormone Disorder Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Hormone Disorder Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Hormone Disorder Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Hormone Disorder Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Hormone Disorder Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hormone Disorder Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Hormone Disorder Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hormone Disorder Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Hormone Disorder Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Hormone Disorder Drug industry.

Chapter 3: Detailed analysis of Hormone Disorder Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Hormone Disorder Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Hormone Disorder Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Hormone Disorder Drug Industry Trends Table 2. Hormone Disorder Drug Industry Drivers Table 3. Hormone Disorder Drug Industry Opportunities and Challenges Table 4. Hormone Disorder Drug Industry Restraints Table 5. Global Hormone Disorder Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Hormone Disorder Drug Revenue Share by Company (2021-2026) Table 7. Global Hormone Disorder Drug Sales Volume by Company (k units) & (2021-2026) Table 8. Global Hormone Disorder Drug Sales Volume Share by Company (2021-2026) Table 9. Global Hormone Disorder Drug Average Price (US$/unit) of Company (2021-2026) Table 10. Global Hormone Disorder Drug Company Ranking, (2024-2026) & (USD Million) Table 11. Global Hormone Disorder Drug Key Company Manufacturing Base & Headquarters Table 12. Global Hormone Disorder Drug Company, Product Type & Application Table 13. Global Hormone Disorder Drug Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Hormone Disorder Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Growth Hormone Stimulator Table 18. Significant Companies of Growth Hormone Inhibitor Table 19. Global Hormone Disorder Drug Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 20. Global Hormone Disorder Drug Sales Volume by Type (2021-2026) & (k units) Table 21. Global Hormone Disorder Drug Sales Volume by Type (2027-2032) & (k units) Table 22. Global Hormone Disorder Drug Sales Volume Share by Type (2021-2026) Table 23. Global Hormone Disorder Drug Sales Volume Share by Type (2027-2032) Table 24. Global Hormone Disorder Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Hormone Disorder Drug Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Hormone Disorder Drug Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Hormone Disorder Drug Sales Value Share by Type (2021-2026) Table 28. Global Hormone Disorder Drug Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Dwarfism Table 30. Significant Companies of Gigantism Table 31. Significant Companies of Other Table 32. Global Hormone Disorder Drug Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 33. Global Hormone Disorder Drug Sales Volume by Application (2021-2026) & (k units) Table 34. Global Hormone Disorder Drug Sales Volume by Application (2027-2032) & (k units) Table 35. Global Hormone Disorder Drug Sales Volume Share by Application (2021-2026) Table 36. Global Hormone Disorder Drug Sales Volume Share by Application (2027-2032) Table 37. Global Hormone Disorder Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Hormone Disorder Drug Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Hormone Disorder Drug Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Hormone Disorder Drug Sales Value Share by Application (2021-2026) Table 41. Global Hormone Disorder Drug Sales Value Share by Application (2027-2032) Table 42. Global Hormone Disorder Drug Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 43. Global Hormone Disorder Drug Sales by Region (2021-2026) & (k units) Table 44. Global Hormone Disorder Drug Sales Market Share by Region (2021-2026) Table 45. Global Hormone Disorder Drug Sales by Region (2027-2032) & (k units) Table 46. Global Hormone Disorder Drug Sales Market Share by Region (2027-2032) Table 47. Global Hormone Disorder Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Hormone Disorder Drug Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Hormone Disorder Drug Sales Value Share by Region (2021-2026) Table 50. Global Hormone Disorder Drug Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Hormone Disorder Drug Sales Value Share by Region (2027-2032) Table 52. Global Hormone Disorder Drug Market Average Price (US$/unit) by Region (2021-2026) Table 53. Global Hormone Disorder Drug Market Average Price (US$/unit) by Region (2027-2032) Table 54. Global Hormone Disorder Drug Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 55. Global Hormone Disorder Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Hormone Disorder Drug Sales by Country (2021-2026) & (k units) Table 57. Global Hormone Disorder Drug Sales Market Share by Country (2021-2026) Table 58. Global Hormone Disorder Drug Sales by Country (2027-2032) & (k units) Table 59. Global Hormone Disorder Drug Sales Market Share by Country (2027-2032) Table 60. Global Hormone Disorder Drug Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Hormone Disorder Drug Sales Value Market Share by Country (2021-2026) Table 62. Global Hormone Disorder Drug Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Hormone Disorder Drug Sales Value Market Share by Country (2027-2032) Table 64. Abbott Company Information Table 65. Abbott Business Overview Table 66. Abbott Hormone Disorder Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 67. Abbott Hormone Disorder Drug Product Portfolio Table 68. Abbott Recent Development Table 69. Teva Pharmaceutical Industries Ltd Company Information Table 70. Teva Pharmaceutical Industries Ltd Business Overview Table 71. Teva Pharmaceutical Industries Ltd Hormone Disorder Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 72. Teva Pharmaceutical Industries Ltd Hormone Disorder Drug Product Portfolio Table 73. Teva Pharmaceutical Industries Ltd Recent Development Table 74. Sun Pharmaceutical Industries Ltd Company Information Table 75. Sun Pharmaceutical Industries Ltd Business Overview Table 76. Sun Pharmaceutical Industries Ltd Hormone Disorder Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 77. Sun Pharmaceutical Industries Ltd Hormone Disorder Drug Product Portfolio Table 78. Sun Pharmaceutical Industries Ltd Recent Development Table 79. Sanofi Company Information Table 80. Sanofi Business Overview Table 81. Sanofi Hormone Disorder Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 82. Sanofi Hormone Disorder Drug Product Portfolio Table 83. Sanofi Recent Development Table 84. Novartis AG Company Information Table 85. Novartis AG Business Overview Table 86. Novartis AG Hormone Disorder Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 87. Novartis AG Hormone Disorder Drug Product Portfolio Table 88. Novartis AG Recent Development Table 89. Merck KGaA Company Information Table 90. Merck KGaA Business Overview Table 91. Merck KGaA Hormone Disorder Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 92. Merck KGaA Hormone Disorder Drug Product Portfolio Table 93. Merck KGaA Recent Development Table 94. Lilly Company Information Table 95. Lilly Business Overview Table 96. Lilly Hormone Disorder Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 97. Lilly Hormone Disorder Drug Product Portfolio Table 98. Lilly Recent Development Table 99. Ferring B.V Company Information Table 100. Ferring B.V Business Overview Table 101. Ferring B.V Hormone Disorder Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 102. Ferring B.V Hormone Disorder Drug Product Portfolio Table 103. Ferring B.V Recent Development Table 104. PT. Daewoong Pharmaceutical Company Company Information Table 105. PT. Daewoong Pharmaceutical Company Business Overview Table 106. PT. Daewoong Pharmaceutical Company Hormone Disorder Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 107. PT. Daewoong Pharmaceutical Company Hormone Disorder Drug Product Portfolio Table 108. PT. Daewoong Pharmaceutical Company Recent Development Table 109. Mayne Pharma Group Limited Company Information Table 110. Mayne Pharma Group Limited Business Overview Table 111. Mayne Pharma Group Limited Hormone Disorder Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 112. Mayne Pharma Group Limited Hormone Disorder Drug Product Portfolio Table 113. Mayne Pharma Group Limited Recent Development Table 114. Ipsen Pharma Company Information Table 115. Ipsen Pharma Business Overview Table 116. Ipsen Pharma Hormone Disorder Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 117. Ipsen Pharma Hormone Disorder Drug Product Portfolio Table 118. Ipsen Pharma Recent Development Table 119. Genentech, Inc Company Information Table 120. Genentech, Inc Business Overview Table 121. Genentech, Inc Hormone Disorder Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 122. Genentech, Inc Hormone Disorder Drug Product Portfolio Table 123. Genentech, Inc Recent Development Table 124. F. Hoffmann-La Roche Ltd Company Information Table 125. F. Hoffmann-La Roche Ltd Business Overview Table 126. F. Hoffmann-La Roche Ltd Hormone Disorder Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 127. F. Hoffmann-La Roche Ltd Hormone Disorder Drug Product Portfolio Table 128. F. Hoffmann-La Roche Ltd Recent Development Table 129. Bausch Health Companies Inc Company Information Table 130. Bausch Health Companies Inc Business Overview Table 131. Bausch Health Companies Inc Hormone Disorder Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 132. Bausch Health Companies Inc Hormone Disorder Drug Product Portfolio Table 133. Bausch Health Companies Inc Recent Development Table 134. Amneal Pharmaceutical Inc Company Information Table 135. Amneal Pharmaceutical Inc Business Overview Table 136. Amneal Pharmaceutical Inc Hormone Disorder Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 137. Amneal Pharmaceutical Inc Hormone Disorder Drug Product Portfolio Table 138. Amneal Pharmaceutical Inc Recent Development Table 139. Key Raw Materials Table 140. Raw Materials Key Suppliers Table 141. Hormone Disorder Drug Distributors List Table 142. Hormone Disorder Drug Customers List Table 143. Research Programs/Design for This Report Table 144. Authors List of This Report Table 145. Secondary Sources Table 146. Primary Sources List of Figures Figure 1. Hormone Disorder Drug Product Image Figure 2. Global Hormone Disorder Drug Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Hormone Disorder Drug Sales Value (2021-2032) & (US$ Million) Figure 4. Global Hormone Disorder Drug Sales (2021-2032) & (k units) Figure 5. Global Hormone Disorder Drug Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Hormone Disorder Drug Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Growth Hormone Stimulator Image Figure 10. Growth Hormone Inhibitor Image Figure 11. Global Hormone Disorder Drug Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 12. Global Hormone Disorder Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Hormone Disorder Drug Sales Volume Share by Type (2021-2032) Figure 14. Global Hormone Disorder Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Hormone Disorder Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Hormone Disorder Drug Sales Value Share by Type (2021-2032) Figure 17. Dwarfism Image Figure 18. Gigantism Image Figure 19. Other Image Figure 20. Global Hormone Disorder Drug Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 21. Global Hormone Disorder Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Hormone Disorder Drug Sales Volume Share by Application (2021-2032) Figure 23. Global Hormone Disorder Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Hormone Disorder Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Hormone Disorder Drug Sales Value Share by Application (2021-2032) Figure 26. Global Hormone Disorder Drug Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 27. Global Hormone Disorder Drug Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Hormone Disorder Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Hormone Disorder Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Hormone Disorder Drug Sales Value (2021-2032) & (US$ Million) Figure 31. North America Hormone Disorder Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Hormone Disorder Drug Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Hormone Disorder Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Hormone Disorder Drug Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Hormone Disorder Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Hormone Disorder Drug Sales Value (2021-2032) & (US$ Million) Figure 37. South America Hormone Disorder Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Hormone Disorder Drug Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Hormone Disorder Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Hormone Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Hormone Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Hormone Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Hormone Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Hormone Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Hormone Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Hormone Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Hormone Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Hormone Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Hormone Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Hormone Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Hormone Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Hormone Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Hormone Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Hormone Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Hormone Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Hormone Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Hormone Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Hormone Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Hormone Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Hormone Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Hormone Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Hormone Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Hormone Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Hormone Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Hormone Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Hormone Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Hormone Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Hormone Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Hormone Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Hormone Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Hormone Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Hormone Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Hormone Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Hormone Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Hormone Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Hormone Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Hormone Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Hormone Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Hormone Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Hormone Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Hormone Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Hormone Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Hormone Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Hormone Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Hormone Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Hormone Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Hormone Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Hormone Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Hormone Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Hormone Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Hormone Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Hormone Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Hormone Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Hormone Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Hormone Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Hormone Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Hormone Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Hormone Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Hormone Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Hormone Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Hormone Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Hormone Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Hormone Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Hormone Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Hormone Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Hormone Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Hormone Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Hormone Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Hormone Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Hormone Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Hormone Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Hormone Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Hormone Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Hormone Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Hormone Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Hormone Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Hormone Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Hormone Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Hormone Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Hormone Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Hormone Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Hormone Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Hormone Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Hormone Disorder Drug Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Hormone Disorder Drug Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Growth Hormone Stimulator
  • Growth Hormone Inhibitor
Applications
  • Dwarfism
  • Gigantism
  • Other
Companies covered
  • Abbott
  • Teva Pharmaceutical Industries Ltd
  • Sun Pharmaceutical Industries Ltd
  • Sanofi
  • Novartis AG
  • Merck KGaA
  • Lilly
  • Ferring B.V
  • PT. Daewoong Pharmaceutical Company
  • Mayne Pharma Group Limited
  • Ipsen Pharma
  • Genentech, Inc
  • F. Hoffmann-La Roche Ltd
  • Bausch Health Companies Inc
  • Amneal Pharmaceutical Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Hormone Disorder Drug Sales Value (2021-2032)
  4. 1.2.2 Global Hormone Disorder Drug Sales Volume (2021-2032)
  5. 1.2.3 Global Hormone Disorder Drug Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Hormone Disorder Drug Market Dynamics
  1. 2.1 Hormone Disorder Drug Industry Trends
  2. 2.2 Hormone Disorder Drug Industry Drivers
  3. 2.3 Hormone Disorder Drug Industry Opportunities and Challenges
  4. 2.4 Hormone Disorder Drug Industry Restraints
3 Hormone Disorder Drug Market by Company
  1. 3.1 Global Hormone Disorder Drug Company Revenue Ranking in 2025
  2. 3.2 Global Hormone Disorder Drug Revenue by Company (2021-2026)
  3. 3.3 Global Hormone Disorder Drug Sales Volume by Company (2021-2026)
  4. 3.4 Global Hormone Disorder Drug Average Price by Company (2021-2026)
  5. 3.5 Global Hormone Disorder Drug Company Ranking (2024-2026)
  6. 3.6 Global Hormone Disorder Drug Company Manufacturing Base and Headquarters
  7. 3.7 Global Hormone Disorder Drug Company Product Type and Application
  8. 3.8 Global Hormone Disorder Drug Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Hormone Disorder Drug Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Hormone Disorder Drug Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Hormone Disorder Drug Market by Type
  1. 4.1 Hormone Disorder Drug Type Introduction
  2. 4.1.1 Growth Hormone Stimulator
  3. 4.1.2 Growth Hormone Inhibitor
  4. 4.2 Global Hormone Disorder Drug Sales Volume by Type
  5. 4.2.1 Global Hormone Disorder Drug Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Hormone Disorder Drug Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Hormone Disorder Drug Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Hormone Disorder Drug Sales Value by Type
  9. 4.3.1 Global Hormone Disorder Drug Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Hormone Disorder Drug Sales Value by Type (2021-2032)
  11. 4.3.3 Global Hormone Disorder Drug Sales Value Share by Type (2021-2032)
5 Hormone Disorder Drug Market by Application
  1. 5.1 Hormone Disorder Drug Application Introduction
  2. 5.1.1 Dwarfism
  3. 5.1.2 Gigantism
  4. 5.1.3 Other
  5. 5.2 Global Hormone Disorder Drug Sales Volume by Application
  6. 5.2.1 Global Hormone Disorder Drug Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Hormone Disorder Drug Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Hormone Disorder Drug Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Hormone Disorder Drug Sales Value by Application
  10. 5.3.1 Global Hormone Disorder Drug Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Hormone Disorder Drug Sales Value by Application (2021-2032)
  12. 5.3.3 Global Hormone Disorder Drug Sales Value Share by Application (2021-2032)
6 Hormone Disorder Drug Regional Sales and Value Analysis
  1. 6.1 Global Hormone Disorder Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Hormone Disorder Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Hormone Disorder Drug Sales by Region: 2021-2026
  4. 6.2.2 Global Hormone Disorder Drug Sales by Region (2027-2032)
  5. 6.3 Global Hormone Disorder Drug Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Hormone Disorder Drug Sales Value by Region (2021-2032)
  7. 6.4.1 Global Hormone Disorder Drug Sales Value by Region: 2021-2026
  8. 6.4.2 Global Hormone Disorder Drug Sales Value by Region (2027-2032)
  9. 6.5 Global Hormone Disorder Drug Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Hormone Disorder Drug Sales Value (2021-2032)
  12. 6.6.2 North America Hormone Disorder Drug Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Hormone Disorder Drug Sales Value (2021-2032)
  15. 6.7.2 Europe Hormone Disorder Drug Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Hormone Disorder Drug Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Hormone Disorder Drug Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Hormone Disorder Drug Sales Value (2021-2032)
  21. 6.9.2 South America Hormone Disorder Drug Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Hormone Disorder Drug Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Hormone Disorder Drug Sales Value Share by Country, 2025 VS 2032
7 Hormone Disorder Drug Country-level Sales and Value Analysis
  1. 7.1 Global Hormone Disorder Drug Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Hormone Disorder Drug Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Hormone Disorder Drug Sales by Country (2021-2032)
  4. 7.3.1 Global Hormone Disorder Drug Sales by Country (2021-2026)
  5. 7.3.2 Global Hormone Disorder Drug Sales by Country (2027-2032)
  6. 7.4 Global Hormone Disorder Drug Sales Value by Country (2021-2032)
  7. 7.4.1 Global Hormone Disorder Drug Sales Value by Country (2021-2026)
  8. 7.4.2 Global Hormone Disorder Drug Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Hormone Disorder Drug Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Hormone Disorder Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Hormone Disorder Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Hormone Disorder Drug Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Hormone Disorder Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Hormone Disorder Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Hormone Disorder Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Hormone Disorder Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Hormone Disorder Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Hormone Disorder Drug Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Hormone Disorder Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Hormone Disorder Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Hormone Disorder Drug Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Hormone Disorder Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Hormone Disorder Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Hormone Disorder Drug Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Hormone Disorder Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Hormone Disorder Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Hormone Disorder Drug Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Hormone Disorder Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Hormone Disorder Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Hormone Disorder Drug Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Hormone Disorder Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Hormone Disorder Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Hormone Disorder Drug Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Hormone Disorder Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Hormone Disorder Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Hormone Disorder Drug Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Hormone Disorder Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Hormone Disorder Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Hormone Disorder Drug Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Hormone Disorder Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Hormone Disorder Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Hormone Disorder Drug Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Hormone Disorder Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Hormone Disorder Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Hormone Disorder Drug Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Hormone Disorder Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Hormone Disorder Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Hormone Disorder Drug Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Hormone Disorder Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Hormone Disorder Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Hormone Disorder Drug Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Hormone Disorder Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Hormone Disorder Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Hormone Disorder Drug Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Hormone Disorder Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Hormone Disorder Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Hormone Disorder Drug Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Hormone Disorder Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Hormone Disorder Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Hormone Disorder Drug Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Hormone Disorder Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Hormone Disorder Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Hormone Disorder Drug Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Hormone Disorder Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Hormone Disorder Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Hormone Disorder Drug Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Hormone Disorder Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Hormone Disorder Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Hormone Disorder Drug Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Hormone Disorder Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Hormone Disorder Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Hormone Disorder Drug Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Hormone Disorder Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Hormone Disorder Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Hormone Disorder Drug Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Hormone Disorder Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Hormone Disorder Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Hormone Disorder Drug Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Hormone Disorder Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Hormone Disorder Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Hormone Disorder Drug Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Hormone Disorder Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Hormone Disorder Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Hormone Disorder Drug Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Hormone Disorder Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Hormone Disorder Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Hormone Disorder Drug Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Hormone Disorder Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Hormone Disorder Drug Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Hormone Disorder Drug Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Hormone Disorder Drug Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Hormone Disorder Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Abbott
  2. 8.1.1 Abbott Company Information
  3. 8.1.2 Abbott Business Overview
  4. 8.1.3 Abbott Hormone Disorder Drug Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Abbott Hormone Disorder Drug Product Portfolio
  6. 8.1.5 Abbott Recent Developments
  7. 8.2 Teva Pharmaceutical Industries Ltd
  8. 8.2.1 Teva Pharmaceutical Industries Ltd Company Information
  9. 8.2.2 Teva Pharmaceutical Industries Ltd Business Overview
  10. 8.2.3 Teva Pharmaceutical Industries Ltd Hormone Disorder Drug Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Teva Pharmaceutical Industries Ltd Hormone Disorder Drug Product Portfolio
  12. 8.2.5 Teva Pharmaceutical Industries Ltd Recent Developments
  13. 8.3 Sun Pharmaceutical Industries Ltd
  14. 8.3.1 Sun Pharmaceutical Industries Ltd Company Information
  15. 8.3.2 Sun Pharmaceutical Industries Ltd Business Overview
  16. 8.3.3 Sun Pharmaceutical Industries Ltd Hormone Disorder Drug Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Sun Pharmaceutical Industries Ltd Hormone Disorder Drug Product Portfolio
  18. 8.3.5 Sun Pharmaceutical Industries Ltd Recent Developments
  19. 8.4 Sanofi
  20. 8.4.1 Sanofi Company Information
  21. 8.4.2 Sanofi Business Overview
  22. 8.4.3 Sanofi Hormone Disorder Drug Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Sanofi Hormone Disorder Drug Product Portfolio
  24. 8.4.5 Sanofi Recent Developments
  25. 8.5 Novartis AG
  26. 8.5.1 Novartis AG Company Information
  27. 8.5.2 Novartis AG Business Overview
  28. 8.5.3 Novartis AG Hormone Disorder Drug Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Novartis AG Hormone Disorder Drug Product Portfolio
  30. 8.5.5 Novartis AG Recent Developments
  31. 8.6 Merck KGaA
  32. 8.6.1 Merck KGaA Company Information
  33. 8.6.2 Merck KGaA Business Overview
  34. 8.6.3 Merck KGaA Hormone Disorder Drug Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Merck KGaA Hormone Disorder Drug Product Portfolio
  36. 8.6.5 Merck KGaA Recent Developments
  37. 8.7 Lilly
  38. 8.7.1 Lilly Company Information
  39. 8.7.2 Lilly Business Overview
  40. 8.7.3 Lilly Hormone Disorder Drug Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Lilly Hormone Disorder Drug Product Portfolio
  42. 8.7.5 Lilly Recent Developments
  43. 8.8 Ferring B.V
  44. 8.8.1 Ferring B.V Company Information
  45. 8.8.2 Ferring B.V Business Overview
  46. 8.8.3 Ferring B.V Hormone Disorder Drug Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Ferring B.V Hormone Disorder Drug Product Portfolio
  48. 8.8.5 Ferring B.V Recent Developments
  49. 8.9 PT. Daewoong Pharmaceutical Company
  50. 8.9.1 PT. Daewoong Pharmaceutical Company Company Information
  51. 8.9.2 PT. Daewoong Pharmaceutical Company Business Overview
  52. 8.9.3 PT. Daewoong Pharmaceutical Company Hormone Disorder Drug Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 PT. Daewoong Pharmaceutical Company Hormone Disorder Drug Product Portfolio
  54. 8.9.5 PT. Daewoong Pharmaceutical Company Recent Developments
  55. 8.10 Mayne Pharma Group Limited
  56. 8.10.1 Mayne Pharma Group Limited Company Information
  57. 8.10.2 Mayne Pharma Group Limited Business Overview
  58. 8.10.3 Mayne Pharma Group Limited Hormone Disorder Drug Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Mayne Pharma Group Limited Hormone Disorder Drug Product Portfolio
  60. 8.10.5 Mayne Pharma Group Limited Recent Developments
  61. 8.11 Ipsen Pharma
  62. 8.11.1 Ipsen Pharma Company Information
  63. 8.11.2 Ipsen Pharma Business Overview
  64. 8.11.3 Ipsen Pharma Hormone Disorder Drug Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Ipsen Pharma Hormone Disorder Drug Product Portfolio
  66. 8.11.5 Ipsen Pharma Recent Developments
  67. 8.12 Genentech, Inc
  68. 8.12.1 Genentech, Inc Company Information
  69. 8.12.2 Genentech, Inc Business Overview
  70. 8.12.3 Genentech, Inc Hormone Disorder Drug Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Genentech, Inc Hormone Disorder Drug Product Portfolio
  72. 8.12.5 Genentech, Inc Recent Developments
  73. 8.13 F. Hoffmann-La Roche Ltd
  74. 8.13.1 F. Hoffmann-La Roche Ltd Company Information
  75. 8.13.2 F. Hoffmann-La Roche Ltd Business Overview
  76. 8.13.3 F. Hoffmann-La Roche Ltd Hormone Disorder Drug Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 F. Hoffmann-La Roche Ltd Hormone Disorder Drug Product Portfolio
  78. 8.13.5 F. Hoffmann-La Roche Ltd Recent Developments
  79. 8.14 Bausch Health Companies Inc
  80. 8.14.1 Bausch Health Companies Inc Company Information
  81. 8.14.2 Bausch Health Companies Inc Business Overview
  82. 8.14.3 Bausch Health Companies Inc Hormone Disorder Drug Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Bausch Health Companies Inc Hormone Disorder Drug Product Portfolio
  84. 8.14.5 Bausch Health Companies Inc Recent Developments
  85. 8.15 Amneal Pharmaceutical Inc
  86. 8.15.1 Amneal Pharmaceutical Inc Company Information
  87. 8.15.2 Amneal Pharmaceutical Inc Business Overview
  88. 8.15.3 Amneal Pharmaceutical Inc Hormone Disorder Drug Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Amneal Pharmaceutical Inc Hormone Disorder Drug Product Portfolio
  90. 8.15.5 Amneal Pharmaceutical Inc Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Hormone Disorder Drug Value Chain Analysis
  2. 9.1.1 Hormone Disorder Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Hormone Disorder Drug Sales Mode & Process
  6. 9.2 Hormone Disorder Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Hormone Disorder Drug Distributors
  9. 9.2.3 Hormone Disorder Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst